Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility

05-Sep-2008 - Australia

The new Monash Antibody Technologies Facility (MATF) was officially opened at a ceremony attended by a number of dignitaries from the Australian government, academia and the life science industry. The newly refurbished, two hundred square meter facility houses cutting-edge equipment and boasts impressive capabilities for high throughput production of custom-made, high-affinity monoclonal antibodies.

Michael Spiegel, deputy director of MATF, said: “In just one year, and with Tecan’s support, we have renovated a whole new space, brought in state-of-the-art, fully automated systems and have them already producing antibodies. This is now the largest capacity and probably the most sophisticated and technologically advanced custom antibody facility in the world. We already have 50 academic projects in the pipeline and we are members of the structural genomic consortium, an international pilot project for creating binding agents to all human proteins and protein binders.“

Other news from the department science

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous